Intestinal Behcet's disease in a 38-year-old woman was diagnosed because of the history of recurrent oral aphthous ulcers, erythema nodosum-like eruptions, genital ulcer, and endoscopic findings of esophageal and ileocolonic punched-out ulcers with colonic longitudinal ulcers. Esophageal lesions and colonic longitudinal ulcers are rarely seen in intestinal Behcet's disease. The ulcers of esophagus and ileocolon healed with 3 wk of treatment with prednisolone and mesalazine without any adverse effect. Mesalazine may decrease the total dose of prednisolone required to treat the disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4088001 | PMC |
| http://dx.doi.org/10.3748/wjg.v12.i16.2622 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case report: Vedolizumab in Oral Crohn's disease: the downsides of a gut-specific therapy for a multi-site disease.
Front Med (Lausanne)
December 2024
Department of Oral Medicine, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom.
Introduction: Crohn's disease (CD) is a chronic inflammatory bowel disease which can affect any area of the gastrointestinal tract, including oral tissues. The complex nature of this disease demands interdisciplinary management, especially when both intestinal and oral manifestations are present.
Case: This report presents the case of a 28-year-old male patient with oral, ileo-caecal and peri-anal CD managed jointly between Gastroenterology and Oral Medicine.
Tuberculosis (TB) is an infectious disease caused by bacteria, which is more prevalent among immunocompromised individuals. According to the distribution of affected organs, this infection can be categorized as either pulmonary or extrapulmonary TB. Immunodeficiency states resulting from rheumatological disorders and the use of immunosuppressive medications, such as in Behçet's disease (BD), are potential predisposing factors for TB, particularly in cases involving multiple organs.
View Article and Find Full Text PDFApplication of allogeneic hematopoietic stem cell transplantation to treat Behcet's disease with myelodysplastic syndrome: a case report and literature review.
Ann Hematol
November 2024
Division of Hematology, Department of Medicine, The First Affiliated Hospital of Harbin Medical University, 23 Youzheng Street, Nan Gang District, Harbin, 150001, Heilongjiang Province, China.
Trisomy 8 is a frequent chromosomal abnormality that occurs among patients with myelodysplastic syndrome (MDS). This abnormality is more common among MDS patients with concurrent Behcet's disease (BD) than among patients with MDS alone. This comorbidity is also associated with a higher prevalence of intestinal ulcers.
View Article and Find Full Text PDFRisk Factors of Reoperation in Patients with Intestinal Behçet's Disease Treated by Initial Bowel Resection.
J Clin Med
November 2024
Division of Colorectal Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
: Intestinal Behçet's disease (iBD) often requires surgical intervention, with a significant proportion of patients needing reoperation. This study aimed to investigate the risk factors associated with reoperation in patients with iBD who underwent initial bowel resection and to evaluate the perioperative and long-term outcomes in these patients. : This was a retrospective case-control study analyzing patients who underwent their initial bowel resection due to iBD between 2005-2021 at a tertiary referral hospital.
View Article and Find Full Text PDFCase report: Successful remission with upadacitinib in a young patient with anti-TNF-refractory intestinal Behçet's disease.
Front Immunol
November 2024
Department of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Article Synopsis
- - The management of Intestinal Behçet's disease is challenging due to limited treatment options and a lack of standardized guidelines.
- - A case study highlights a patient who struggled with the disease despite previous biologic treatments but found success with the JAK inhibitor Upadacitinib, leading to mucosal healing.
- - This case suggests that Upadacitinib could be a promising alternative for patients who do not respond to traditional therapies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!